If a pharmaceutical researcher introduces a novel molecule that selectively enhances coactivator binding to estrogen receptors (ER) within a cell nucleus, which consequence follows?

💡 Explanation

Enhancing coactivator binding to nuclear estrogen receptors directly promotes assembly of the transcriptional complex, because this enhances the ability of the receptor to activate gene expression. Therefore, ER-mediated gene transcription increases, rather than other effects such as inhibiting dimerization which is a separate step.

• Why does legume growth often improve when Bradyrhizobium bacteria are present in soil?
• What happens to the targeted DNA sequence following a Cas9-mediated double-strand break and homology-directed repair?
• What causes plant mitochondrial genes to occasionally appear in the nuclear genome?
• If luciferase activity is measured in fireflies, what happens to the emitted light's intensity when ATP concentration decreases?
• What happens to blood glucose levels when insulin resistance increases significantly in peripheral tissues?
• A researcher treats induced pluripotent stem cells (iPSCs) with retinoic acid, aiming to differentiate them. Which outcome follows if the signaling cascade activates lineage-specific transcription factors?